Transcatheter Valve Repair System Market Report 2026

Transcatheter Valve Repair System Market Overview

• Transcatheter Valve Repair System market size has reached to $5.45 billion in 2025 • Expected to grow to $8.42 billion in 2030 at a compound annual growth rate (CAGR) of 9.2% • Growth Driver: Increasing Incidence Of Heart Diseases Fuels Growth In The Transcatheter Valve Repair System Market • Market Trend: Durability-Enhanced Transcatheter Valves Advance Long-Term Outcomes In Aortic Therapy • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Transcatheter Valve Repair System Market?

A transcatheter valve repair system is a minimally invasive procedure that involves inserting a catheter through a small incision in the leg or chest and guiding it to the heart using imaging guidance. It is used to treat patients with severe (grade 3+ or above) mitral regurgitation brought on by aberrant mitral valve leaflets and the region around the leaflets when open-heart surgery is deemed too dangerous. The main products of transcatheter valve repair system are transcatheter aortic valve replacement (TAVR), transcatheter mitral valve replacement (TMVR), transcatheter pulmonary valve replacement (TPVR), and transcatheter tricuspid valve replacement (TTVR). Transcatheter Aortic Valve Replacement (TAVR) refers to the replacement of an aortic valve with aortic valve stenosis, a minimally invasive heart treatment. It is used to improve blood flow and lessen aortic valve stenosis symptoms like exhaustion, shortness of breath, fainting, and chest pain. The applications of transcatheter valve repair systems include aortic stenosis, mitral stenosis, tricuspid stenosis, and pulmonary stenosis which are used in hospitals, specialty clinics, ambulatory surgical centers, and others.

What Is The Transcatheter Valve Repair System Market Growth Forecast?

The transcatheter valve repair system market size is expected to see strong growth in the next few years. It will grow to $8.42 billion in 2030 at a compound annual growth rate (CAGR) of 9.2%. The growth in the forecast period can be attributed to increasing adoption of minimally invasive valve repair, rising demand for transcatheter mitral interventions, expansion of structural heart disease programs, growing innovation in multi-valve repair technologies, increasing focus on patient-specific treatment solutions. Major trends in the forecast period include increasing adoption of catheter-based valve repair procedures, rising demand for mitral valve repair systems, growing focus on high-risk surgical patients, expansion of multi-valve repair platforms, enhanced device navigability and control.

What Is The Driver Of The Transcatheter Valve Repair System Market?

The rise in the incidence of heart diseases is expected to propel the growth of the transcatheter valve repair system market going forward. Heart disease refers to a condition that affects the blood vessels or the heart. Transcatheter devices are used to replace a defective aortic valve with an artificial valve in the treatment of valvular heart disease, specifically aortic valve disease. For instance, in March 2024, according to Office for Health Improvement and Disparities (OHID), a Ul-based government department, in England, roughly 1,862,500 persons (3%) had a GP diagnosis of CHD in the fiscal year that ended in 2023. Therefore, the rise in the incidence of heart disease is driving the growth of the transcatheter valve repair system industry.

Key Players In The Global Transcatheter Valve Repair System Market

Major companies operating in the transcatheter valve repair system market are Abbott Laboratories, Medtronic Plc., Boston Scientific Corporation, Edwards Lifesciences Corporation, LivaNova Plc., Meril Life Sciences Pvt. Ltd., Cordis Corporation, MicroPort Scientific Corporation., Biotronik Pvt. Ltd, AtriCure Inc., OrbusNeich Medical Group Holdings Limited, Venus Medtech (Hangzhou) Inc., Dura LLC, HLT Medical Inc., Symetis SA, JenaValve Technology Inc., 4C Medical Technologies Inc., Cardiac Dimensions Inc., Valve Solutions Inc., Transcatheter Technologies GmbH, Evalve Corporation, Colibri Heart Valve LLC, Medtentia International Ltd., Coramaze Technologies Ltd., Neovasc Inc., Anteris Technologies Ltd.

Global Transcatheter Valve Repair System Market Trends and Insights

Major companies operating in the transcatheter valve repair system market are focusing on developing innovative advancements such as durability-enhanced transcatheter valves to increase long-term valve durability and optimize clinical outcomes for patients undergoing transcatheter valve replacement. A durability-enhanced transcatheter valve is a minimally invasive aortic replacement device constructed with advanced biomaterials to improve structural longevity and sustain effective valve function over time. For instance, in May 2024, Edwards Lifesciences, a Switzerland-based provider of structural heart and critical care technologies, launched the SAPIEN 3 Ultra RESILIA valve. The device incorporates a proprietary anti-calcification tissue technology intended to reduce structural deterioration and support long-term performance. It also offers dry-tissue storage and demonstrated favorable early hemodynamic outcomes, underscoring its potential to enhance durability and broaden treatment options for patients with aortic valve disease.

What Are Latest Mergers And Acquisitions In The Transcatheter Valve Repair System Market?

In October 2024, Edwards Lifesciences, a US-based provider of structural heart therapies and transcatheter repair and replacement technologies, acquired Innovalve Bio Medical Ltd. for an undisclosed amount. With this acquisition, Edwards aims to strengthen its transcatheter mitral and tricuspid therapy portfolio by enhancing its technology platform for next-generation mitral valve replacement and expanding its ability to address unmet needs in structural heart disease. Innovalve Bio Medical Ltd. is an Israel-based provider of early-stage transcatheter mitral valve replacement technologies designed to treat complex mitral valve pathologies.

What Defines the Transcatheter Valve Repair System Market?

The transcatheter valve repair systems market includes revenues earned by entities by providing mitraClip G4 system, NeoChord, harpon, and PaScal precision transcatheter. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Transcatheter Valve Repair System Market Report 2026?

The transcatheter valve repair system market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the transcatheter valve repair system industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.